Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone925-288-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.91 million
Profitability
Miscellaneous
Employees240
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Tuesday, February, 26th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.02. The biotechnology company earned $16.50 million during the quarter, compared to the consensus estimate of $18.74 million. Cerus had a negative return on equity of 65.35% and a negative net margin of 84.15%. The company's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) EPS. View Cerus' Earnings History.
When is Cerus' next earnings date?
What guidance has Cerus issued on next quarter's earnings?
Cerus issued an update on its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $70-73 million, compared to the consensus revenue estimate of $94.05 million.
What price target have analysts set for CERS?
3 brokerages have issued 1-year target prices for Cerus' stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Cerus' share price to reach $9.50 in the next year. This suggests a possible upside of 61.0% from the stock's current price. View Analyst Price Targets for Cerus.
What is the consensus analysts' recommendation for Cerus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.
What are Wall Street analysts saying about Cerus stock?
Here are some recent quotes from research analysts about Cerus stock:
- 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (3/4/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate CERS Overweight and have a 12-month price target of $9. CERS commercializes INTERCEPT, the only FDA-approved system for pathogen- inactivated (PI) blood components. We believe 2019 will be a pivotal year for the company as it continues to penetrate the platelet transfusion market in key geographical regions (US and internationally), which we expect to drive double-digit revenue growth longer term. CERS is seeking regulatory approval in Europe and the US to use its INTERCEPT system to treat red cells, a company-estimated $5B market." (12/18/2018)
Has Cerus been receiving favorable news coverage?
News articles about CERS stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Mazor Robotics (MZOR), K2M Group (KTWO), Cardiovascular Systems (CSII), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD) and Intersect ENT (XENT).
What other stocks do shareholders of Cerus own?
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 52)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)
Who are Cerus' major shareholders?
Cerus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.41%) and Virtu Financial LLC (0.01%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.
Which major investors are selling Cerus stock?
CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.
Which major investors are buying Cerus stock?
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $5.90.
How big of a company is Cerus?
Cerus has a market capitalization of $808.02 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.
What is Cerus' official website?
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (NASDAQ CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
